Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Tangram Therapeutics

Next Previous
Drug Profile

Research programme: small molecule therapeutics - Tangram Therapeutics

Alternative Names: ETS 2123; ETS 5200; ETS 6114; ETS 7211; ETS-6200; ETS2300; ETS2400; ETX 6201; ETX 6765; ETXP-009171; ETXP-009181; ETXP-009425

Latest Information Update: 07 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator e-Therapeutics
  • Developer e-Therapeutics; Tangram Therapeutics
  • Class Small molecules
  • Mechanism of Action Hedgehog cell signalling pathway inhibitors; Protein modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Fibrosis; Neurodegenerative disorders; Viral infections
  • Discontinued Age-related macular degeneration; Pain

Most Recent Events

  • 01 Oct 2025 e-Therapeutics is now called Tangram Therapeutics
  • 28 Apr 2022 No recent reports of development identified for research development in Fibrosis in United Kingdom
  • 28 Aug 2021 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top